Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer's disease. A systematic review of randomized controlled trials

Ageing Research Reviews

Volumn 16, Issue 1, 2014, Pages 105-112

  Rijpma, A ^a   Meulenbroek, O ^a,b   Olde Rikkert, M G M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY   (Netherlands)

Author keywords

Alzheimer's disease; Cognition; Complex interventions; Dementia; Multidomain; Nutrition

Indexed keywords

ACETYLCHOLINE; ALPHA TOCOPHEROL; CHOLINESTERASE INHIBITOR; HOMOCYSTEINE;

ADD ON THERAPY; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; BIOLOGICAL ACTIVITY; CLINICAL EFFECTIVENESS; COGNITION; DRUG EFFECT; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; FUNCTIONAL STATUS; GERIATRIC NUTRITION; HUMAN; INFLAMMATION; MEMBRANE FLUIDITY; META ANALYSIS; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION; AGED; DIET SUPPLEMENTATION; DRUG COMBINATION; DRUG EFFECTS; ENZYMOLOGY; FEMALE; MALE; NUTRITIONAL STATUS; PSYCHOLOGY; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; NUTRITIONAL STATUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84904249209     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2014.06.002     Document Type: Review

References (43)

1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S.T., Hampel H., Hull M., Landreth G., Lue L.F., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421. Neuroinflammation Working Group.
2. Amenta F., Carotenuto A., Fasanaro A.M., Rea R., Traini E. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results. J. Neurol. Sci. 2012, 322:96-101.
3. Arlt S., Müller-Thomsen T., Beisiegel U., Kontush A. Effect of one-year vitamin C- and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer's disease. Neurochem. Res. 2012, 37:2706-2714.
4. Balk E.M., Raman G., Tatsioni A., Chung M., Lau J., Rosenberg I.H. Vitamin b6, b12, and folic acid supplementation and cognitive function: a systematic review of randomized trials. Arch. Intern. Med. 2007, 167:21-30.
5. Barnett-Norris J., Lynch D., Reggio P.H. Lipids, lipid rafts and caveolae: their importance for GPCR signaling and their centrality to the endocannabinoid system. Life Sci. 2005, 77:1625-1639.
6. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-417.
7. Bourre J.M. Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 1: Micronutrients. J. Nutr. Health Aging 2006, 10:377-385.
8. Chauhan V., Chauhan A. Oxidative stress in Alzheimer's disease. Pathophysiology 2006, 13:195-208.
9. Clarke R., Smith A.D., Jobst K.A., Refsum H., Sutton L., Ueland P.M. Folate, vitamin B-12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch. Neurol. 1998, 55:1449-1455.
10. Connelly P.J., Prentice N.P., Cousland G., Bonham J. A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. Int. J. Geriatr. Psychiatry 2008, 23:155-160.
11. Cornelli U. Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants. Neurodegener. Dis. 2010, 7:193-202.
12. Dangour A.D., Whitehouse P.J., Rafferty K., Mitchell S.A., Smith L., Hawkesworth S., Vellas B. B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: a systematic review. J. Alzheimers Dis. 2010, 22:205-224.
13. Douaud G., Refsum H., de Jager C.A., Jacoby R., Nichols E., Smith T., Smith S.M.A.D. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc. Natl. Acad. Sci. U.S.A. 2013, [Epub ahead of print]. 10.1073/pnas.1301816110.
14. Dysken M.W., Sano M., Asthana S., Vertrees J.E., Pallaki M., Llorente M., Love S., Schellenberg G.D., McCarten J.R., Malphurs J., Prieto S., Chen P.J., Loreck D.J., Trapp G., Bakshi R.S., Mintzer J.E., Heidebrink J.L., Vidal-Cardona A., Arroyo L.M., Cruz A.R., Zachariah S., Kowall N.W., Chopra M.P., Craft S., Thielke S., Turvey C.L., Woodman C., Monnell K.A., Gordon K., Tomaska J., Segal Y., Peduzzi P.N., Guarino P.D. Effect of vitamin E and memantine on functional decline in Alzheimer disease the TEAM-AD VA cooperative randomized trial. J. Am. Med. Assoc. 2014, 311:33-44.
15. Eckert G.P., Cairns N.J., Maras A., Gattaz W.F., Muller W.E. Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2000, 11:181-186.
16. Excellence, N.I.f.H.a.C. NICE technology appraisal guidance 217. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of NICE technology appraisal guidance 111) 2011, Excellence, N.I.f.H.a.C., London.
17. Faes M.C., Reelick M.F., Esselink R.A., Rikkert M.G.O. Developing and evaluating complex healthcare interventions in geriatrics: the use of the medical research council framework exemplified on a complex fall prevention intervention. J. Am. Geriatr. Soc. 2010, 58:2212-2221.
18. Foster N.L., Petersen R.C., Gracon S.I., Lewis K. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. Dementia 1996, 7:260-266.
19. Freund-Levi Y., Eriksdotter-Jonhagen M., Cederholm T., Basun H., Faxen-Irving G., Garlind A., Vedin I., Vessby B., Wahlund L.-O., Palmblad J. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study - a randomized double-blind trial. Arch. Neurol. 2006, 63:1402.
20. Freund-Levi Y., Hjorth E., Lindberg C., Cederholm T., Faxen-Irving G., Vedin I., Palmblad J., Wahlund L.-O., Schultzberg M., Basun H., Jonhagen M.E. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dement. Geriatr. Cogn. Disord. 2009, 27:481-490.
21. Heiss W.D., Kessler J., Mielke R., Szelies B., Herholz K. Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease. A neuropsychological, EEG, and PET investigation. Dementia 1994, 5:88-98.
22. Higgins J., Green S. Cochrane Handbook for Systematic Reviews of Interventions 2011, The Cochrane Collaboration.
23. Isaac M.G.E.K.N., Quinn R., Tabet N. Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst. Rev. 2008, (3). Article ID: CD002854. 10.1002/14651858.CD002854.pub2.
24. Issa A.M., Mojica W.A., Morton S.C., Traina S., Newberry S.J., Hilton L.G., Garland R.H., MacLean C.H. The efficacy of omega-3 fatty acids on cognitive function in aging and dementia: a systematic review. Dement. Geriatr. Cogn. Disord. 2006, 21:88-96.
25. Lee L.K., Shahar S., Chin A.-V., Yusoff N.A.M. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2013, 225:605-612.
26. Lloret A., Badia M.C., Mora N.J., Pallardo F.V., Alonso M.D., Vina J. Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J. Alzheimers Dis. 2009, 17:143-149.
27. Lopes da Silva S., Elemans S., Kamphuis P., Sijben J., Groenendijk M. Plasma nutrient status of Alzheimer's disease patients compared to cognitive intact elderly controls. A systematic review and meta-analysis. Alzheimer's Dement. 2012, 8:P216.
28. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 1997, 23:134-147.
29. Moehler R., Bartoszek G., Koepke S., Meyer G. Proposed criteria for reporting the development and evaluation of complex interventions in healthcare (CReDECI): guideline development. Int. J. Nurs. Stud. 2012, 49:40-46.
30. Moher D., Liberati A., Tetzlaff J., Altman D.G., Grp P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 2009, 151:264-269. W264.
31. Morris M.C. The role of nutrition in Alzheimer's disease: epidemiological evidence. Eur. J. Neurol. 2009, 16:1-7.
32. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Aggarwal N., Scheider J., Wilson R.S. Dietary fats and the risk of incident Alzheimer disease. Arch. Neur. 2003, 60:1072.
33. Obeid R., Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett. 2006, 580:2994-3005.
34. Olde Rikkert M.G.M., van der Flier W.M., de Leeuw F.-E., Verbeek M., Jansen R.W.M.M., Verhey F., Scheltens P. Multiple diagnostic tests are needed to assess multiple causes of dementia. Arch. Neurol. 2006, 63:144-146.
35. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., Galasko D., Jin S., Kaye J., Levey A., Pfeiffer E., Sano M., van Dyck C.H., Thal L.J. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 2005, 352:2379-2388. Alzheimer's Disease Cooperative Study Group.
36. Pratico D. Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol. Sci. 2008, 29:609-615.
37. Richard E., Schmand B., Eikelenboom P., Westendorp R.G., Van Gool W.A. The Alzheimer myth and biomarker research in dementia. J. Alzheimers Dis. 2012, 31:S203-S209.
38. Scheltens P., Twisk J.W.R., Blesa R., Scarpini E., von Arnim C.A.F., Bongers A., Harrison J., Swinkels S.H.N., Stam C.J., de Waal H., Wurtman R.J., Wieggers R.L., Vellas B., Kamphuis P.J.G.H. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J. Alzheimers Dis. 2012, 31:225-236.
39. Shah R., Kamphuis P., Lerugans S., Swinkels S., Sadowsky C., Bongers A., Rappaport S., Quinn J., Wieggers R., Bennett D., Scheltens P. Souvenaid as an add-on intervention in patients with mild to moderate Alzheimer's disease using Alzheimer's disease medication: results from a randomized, controlled, double-blind study (S-Connect). 4th Conference Clinical Trials on Alzheimer's Disease. J. Nutr. Health Aging 2011, S30.
40. Shah R.C., Kamphuis P.J., Leurgans S., Swinkels S.H., Sadowsky C.H., Bongers A., Rappaport S.A., Quinn J.F., Wieggers R.L., Scheltens P., Bennett D.A. The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. Alzheimers Res. Ther. 2013, 5:59.
41. Sun Y., Lu C.-J., Chien K.-L., Chen S.-T., Chen R.-C. Efficacy of multivitamin supplementation containing vitamins B-6 and B-12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. Clin. Ther. 2007, 29:2204-2214.
42. van der Vlies A.E., Verwey N.A., Bouwman F.H., Blankenstein M.A., Klein M., Scheltens P., van der Flier W.M. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 2009, 72:1056-1061.
43. van Uffelen J.G.Z., Chinapaw M.J.M., van Mechelen W., Hopman-Rock M. Walking or vitamin B for cognition in older adults with mild cognitive impairment? A randomised controlled trial. Br. J. Sports Med. 2008, 42.